Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06124261
Other study ID # 23-39040
Secondary ID 1R01DK134633-01A
Status Recruiting
Phase
First received
Last updated
Start date January 22, 2024
Est. completion date December 2028

Study information

Verified date June 2024
Source University of California, San Francisco
Contact Elle K Oberweis-Manion, B.A.
Phone 415-502-3725
Email elle.oberweismanion@ucsf.edu
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time. NAFLD happens when fat builds up in the liver which can cause damage to the liver such as inflammation or scarring. Young women with a condition called polycystic ovary syndrome (PCOS) have a high risk for NAFLD, and they often have high androgen levels too. So the researchers are recruiting young women with PCOS as well as those without PCOS, and will compare changes in NAFLD over time between young women with and without PCOS. This study is funded by the National Institutes of Health


Description:

The studies central hypothesis is that androgens promote liver injury and NAFLD/NASH progression in PCOS, which occurs through aberrant lipid activity (including lipotoxicity and dysregulated de novo lipogenesis), in part from androgenic effects on visceral adipose tissue (VAT). Data in young women taking exogenous testosterone show redistribution of fat from subcutaneous to visceral stores In the general population, VAT promotes NASH through several established pathways, including production of tissue injurious or "lipotoxic" lipids such as some phospholipid, sphingomyelin, and ceramide species. Recent data show androgen- associated increase in serum glycerophospholipids in women with PCOS, a lipid class that is associated with NASH in women. Additionally, androgen-associated de novo lipogenesis (DNL) may contribute to NASH in women. Hepatic DNL is a key source of lipid accumulation, and co-investigators at Duke University recently discovered an enzymatic balance that regulates hepatic DNL with dysregulation of this pathway (reflected by branched-chain keto and amino acids) predictive of prevalent NASH in humans. Androgen-induced de novo lipogenesis also occurs in cultured hepatocytes from women (but not men) supporting the researchers focused evaluation of the relationship between androgens, dysregulated hepatic DNL, and NASH in PCOS. As existing data support androgenic effects on hepatic and visceral fat in women, the researchers will now determine the relationship of androgens with liver injury and progression in PCOS and the potential mechanistic contributions of VAT and aberrant lipid metabolism to this process. The team includes clinical and translational researchers at two centers (UCSF and Duke) with expertise in NAFLD, PCOS, obesity, and lipid metabolism, with a track record of collaboration. The study team will leverage an existing well-characterized PCOS cohort29 to follow 150 reproductive-aged women with NASH (125 PCOS and 25 non-PCOS controls) to accomplish this.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date December 2028
Est. primary completion date December 2028
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Metabolic associated steatohepatitis (MASH) (formerly NASH) - PCOS - Non-PCOS Exclusion Criteria: - High levels of alcohol use (more than 7 drinks a week) - Current pregnancy - Other causes of hepatic steatosis - Weight loss of more than 10% body weight in the last 6 months

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Duke University Durham North Carolina
United States University of California San Francisco San Francisco California

Sponsors (3)

Lead Sponsor Collaborator
University of California, San Francisco Duke University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Sarkar M, Terrault N, Chan W, Cedars MI, Huddleston HG, Duwaerts CC, Balitzer D, Gill RM. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver Int. 2020 Feb;40(2):355-359. doi: 10.1111/liv.14279. Epub 2019 Nov 12. — View Citation

Sarkar M, Terrault N, Duwaerts CC, Tien P, Cedars MI, Huddleston H. The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. Curr Opin Gynecol Obstet. 2018 Feb 20;1(1):24-33. Epub 2018 Apr 5. — View Citation

Sarkar M, Yates K, Suzuki A, Lavine J, Gill R, Ziegler T, Terrault N, Dhindsa S. Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in Men. Clin Gastroenterol Hepatol. 2021 Feb;19(2):400-402.e2. doi: 10.1016/j.cgh.2019.11.053. Epub 2019 Dec 5. — View Citation

Sarkar MA, Suzuki A, Abdelmalek MF, Yates KP, Wilson LA, Bass NM, Gill R, Cedars M, Terrault N; NASH Clinical Research Network. Testosterone is Associated With Nonalcoholic Steatohepatitis and Fibrosis in Premenopausal Women With NAFLD. Clin Gastroenterol Hepatol. 2021 Jun;19(6):1267-1274.e1. doi: 10.1016/j.cgh.2020.09.045. Epub 2020 Oct 1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Liver Stiffness Change Mean change in liver stiffness (kPA) on magnetic resonance elastography (MRE) from baseline to Year 3 follow- up.
Primary Visceral Adipose Tissue (VAT) association to MASH severity VAT volume (cm3) will be determined on magnetic resonance electrography (MRE) at baseline
Secondary Liver stiffness severity Severity of liver stiffness will be determined on magnetic resonance electrography (MRE) at baseline
See also
  Status Clinical Trial Phase
Completed NCT06101433 - The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A N/A
Completed NCT03289897 - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan N/A
Active, not recruiting NCT05479721 - LITMUS Imaging Study
Completed NCT05527938 - Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children N/A
Recruiting NCT06308757 - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis N/A
Completed NCT02654977 - CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Phase 2
Completed NCT02927184 - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease Phase 2
Completed NCT06047847 - Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption N/A
Active, not recruiting NCT03534908 - Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study
Recruiting NCT06098417 - Biomarkers in the Diagnosis and Prognosis of NAFLD
Recruiting NCT04564391 - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins N/A
Not yet recruiting NCT05984745 - Effect of CoQ10 on the Outcome of MAFLD Patients Phase 2
Not yet recruiting NCT05052515 - The Effects of Natural Extracts Supplementation on NASH Patients N/A
Recruiting NCT02459496 - Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus N/A
Completed NCT01936779 - Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans N/A
Completed NCT05844137 - Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes N/A
Recruiting NCT04664036 - Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus
Recruiting NCT04976283 - Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver Phase 4
Recruiting NCT03587298 - Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
Completed NCT02952170 - Impact of Weight Loss Surgery in Adolescents With NAFLD N/A